Fulcrum Therapeutics, Inc. Lawsuit Submission Form | Securities Class Action Lawyers

Return to Home

Fulcrum Therapeutics, Inc.

FULC

Find Out if You Qualify for a Financial Reward by filling out the form below.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Owned

Purchase Date

Estimated Loss

Securities Fraud News does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

Fulcrum announced on September 12, 2024, that “its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo. In addition, secondary endpoints did not achieve nominal statistical significance.”

Following this news, Fulcrum stock dropped 60% in morning trading on the same day.

Ticker Symbol	Company Name	Join Deadline
SWKS	Skyworks Solutions, Inc.	May 05, 2025	Join
SWKS	Skyworks Solutions, Inc.	May 05, 2025	Join

Fulcrum Therapeutics, Inc.

FULC

Fulcrum Therapeutics, Inc. Form

Find More Cases